|
|||||
|
|
The Commission's AstraZeneca decision: delaying generic entry is an abuse of a dominant position |
|
| Authors: | Lawrance Sophie; Treacy Pat |
| Abstract: | The European Commission's recent AstraZeneca decision introducesabuse of the patent system as a novel type of infringement ofArticle 82 EC. |
| Keywords: | |
| 本文献已被 Oxford 等数据库收录！ | |